Key Takeaways BSX's Endoscopy revenues rose 6% to $673M in Q1 2025, making up 14% of total company sales. Growth was fueled by strong global demand and high adoption of BSX's advanced GI treatment technologies. Boston Scientific's AXIOS, OverStitch, and MANTIS tools saw double-digit growth, driving segmental momentum.Boston Scientific’s (BSX) Endoscopy business develops and manufactures devices to diagnose and treat a broad range of gastrointestinal (GI) conditions using innovative, less invasive technolo ...